Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710302 | 0.94 | HIF1A (0.43) | HIF1AGRIK1BRD4NPC1ALDH1A1 | |
| SCHEMBL6709830 | 0.92 | BRD4 (0.39) | HIF1AGRIK1BRD4PTPN2PTPN1 | |
| SCHEMBL6713561 | 0.90 | BRD4 (0.38) | HIF1ABRD4PTPN2PTPN1PTPN5 | |
| SCHEMBL6710483 | 0.88 | HIF1A (0.46) | HIF1AGRIK1BRD4ALDH1A1 | |
| SCHEMBL6710314 | 0.87 | HIF1A (0.41) | HIF1ABRD4NPC1ALDH1A1PTPN2 | |
| SCHEMBL6710209 | 0.86 | HIF1A (0.46) | HIF1AGRIK1ALDH1A1LMNARAB9A | |
| SCHEMBL6709902 | 0.86 | HIF1A (0.44) | HIF1AGRIK1ROCK1 | |
| SCHEMBL6708931 | 0.85 | GRIK1 (0.37) | HIF1AGRIK1BRD4PTPN2PTPN1 | |
| SCHEMBL6708990 | 0.84 | HIF1A (0.51) | HIF1AGRIK1ROCK1 | |
| SCHEMBL6708781 | 0.84 | HIF1A (0.45) | HIF1AGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HIF1A 296/4885GRIK1 3885/4885BRD4 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.